Montpellier Capital Risque 2025: Doctreen confirms its strategic positioning with investors

On 7 November, Doctreen took part in Montpellier Capital Risque, an event bringing together some sixty investors and 17 promising start-ups supported by the Montpellier BIC (Business & Innovation Centre).

Our presence among the most eagerly awaited projects highlighted a central need in the medical sector: making report production more reliable and consistent, while easing practitioners' cognitive load.

Doctreen is mentioned in Hubert Vialatte's column Les Indiscrétions.

A solution at the crossroads of AI and clinical expertise

We develop intelligent report-writing solutions based on a combination of artificial intelligence and medical expertise embedded in decision trees.

This hybrid approach addresses three major market challenges:

standardising practices and complying with international guidelines,
saving time for medical teams,
improving patient follow-up through complete and consistent documents.

Discussions on site confirmed investors' growing interest in AI solutions that are responsible, reliable and immediately useful in clinical practice.

Solid traction in a market undergoing transformation

Montpellier Capital Risque confirmed market interest in technologies capable of delivering:

immediate impact in clinical practice,
simple adoption,
seamless integration,
a high level of safety and explainability in the use of AI.

Our approach stands out through a unique combination of AI and structured medical logic, an advanced level of product maturity and a vision firmly rooted in clinical reality.

A supportive ecosystem

The support of the Montpellier BIC played a structuring role in refining our pitch, making it clearer and more impact-oriented.

The momentum of the local ecosystem, particularly strong in healthtech and AI, reinforces our trajectory in a market undergoing rapid transformation.

Conclusion

Our participation in Montpellier Capital Risque marks a key milestone in our development.

It strengthens our credibility with investors.

We are pursuing our mission: putting artificial intelligence and clinical expertise at the service of more reliable, more consistent and more sustainable medicine.